<i>;</i>	Application No. Applicant(s)		
Notice of Allowability	09/903,248	9/903,248 WANDS ET AL.	
	Examiner	Art Unit	
	Karen A Canella	1642	
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED i ) or other appropriate comm IGHTS. This application is	n this application. If not included unication will be mailed in due cour	rse. <b>THIS</b>
1. This communication is responsive to			
2. The allowed claim(s) is/are <u>29, 31, 34,-36, 39-42, 45-47, 5 respectively</u> .	<u>1, 52, 54, 56 and 59-62, rer</u>	numbered as 1, 2, 16-18, 7-15, 19,	20 and 3-6,
3. $\square$ The drawings filed on $\_\_\_$ are accepted by the Examine	r.		
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority unallocation.</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have</li> </ul>	*	or (f).	A
2.   Certified copies of the priority documents have	been received in Application	on No	ί.
3.  Copies of the certified copies of the priority do	cuments have been receive	d in this national stage application	from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file IENT of this application.	e a reply complying with the require	ments
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EX es reason(s) why the oath o	AMINER'S AMENDMENT or NOTION of the control of the	CE OF
6.  CORRECTED DRAWINGS ( as "replacement sheets") mus	st be submitted.		
(a) 🛛 including changes required by the Notice of Draftspers	on's Patent Drawing Review	w ( PTO-948) attached	
1) ⊠ hereto or 2) ☐ to Paper No./Mail Date	•		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment o	r in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the header according to 37 CF	he drawings in the front (not the back	k) of
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MAT	ERIAL must be submitted. Note	the
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of In	formal Patent Application (PTO-15:	2)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		w Summary (PTO-413),	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	8), 7. ⊠ Examiner's	/Mail Date Amendment/Comment	
4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. 🗌 Examiner's	Statement of Reasons for Allowand	ce
of Biological Material	9. 🔲 Other		
			:

Application/Control Number: 09/903,248

Art Unit: 1642

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ingrid Beattie on April 1, 2004.

The application has been amended as follows:

Claims 33 and 43 have been canceled.

Claim 29 has been substituted with the following:

29. A monoclonal antibody that binds to an epitope within the catalytic domain of HAAH, wherein said antibody binds to residues 650-700 of SEQ ID NO:2.

Claim 34 has been substituted with the following:

34. A kit for the diagnosis of a tumor in a mammal comprising a monoclonal antibody that binds to an epitope with the catalytic domain of HAAH, wherein said antibody binds to residues 650-700 of SEQ ID NO:2.

Claim 39 has been substituted with the following:

Application/Control Number: 09/903,248

Art Unit: 1642

39. A monoclonal antibody or a fragment thereof, wherein said antibody or fragment thereof binds to an epitope of SEQ ID NO:2, and wherein said antibody is produced by hybridoma ATCC designation PTA 3386.

Page 3

### Claim 51 has been substituted with the following:

51. The composition of claim 45, wherein said cytotoxic agent is ricin.

### Claim 52 has been substituted with the following:

52. The composition of claim 45, wherein said cytotoxic agent is diphtheria toxin.

## Claim 59 has been added:

59. A monoclonal antibody 5C7 produced by hybridoma ATCC designation PTA 3383.

### Claim 60 has been added:

60. A monoclonal antibody 19B produced by hybridoma ATCC designation 3384.

### Claim 61 has been added:

61. A monoclonal antibody 86A produced by hybridoma ATCC designation 3385.

# Claim 62 has been added:

62. A monoclonal antibody FB501 produced by hybridoma ATCC designation 3386.

Art Unit: 1642

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 10 a.m. to 9 p.m. M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (571)272-0871. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella, Ph.D. Art Unit 1642

Harm J. Gamella ARENA. CANELLA PH.D